Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic … (NCT03009708) | Clinical Trial Compass
CompletedNot Applicable
Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen
France15 participantsStarted 2017-03-21
Plain-language summary
Traditionally known for their role in haemostasis, platelets have also an immune role.
Platelets play a key role in immune mediator secretion, and interact with innate and adaptive immune cells, contributing to the fight against pathogens, as viruses.
Cytomegalovirus (CMV) is responsible of allograft patients' serious infections, because of the induced immune depression. Platelets activation for patients is not determined during the post-graft period, and platelet induced inflammation following a CMV infection is not described.
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients who received an allogeneic haematopoietic stem cell transplant for less than 2 months for any indication ;
* Platelets \> 20 G / L (Giga per Litre) for at least 7 days without transfusion support ;
* Patients affiliated to a social security scheme.
Exclusion Criteria:
* Patients receiving antiplatelet therapy ;
* Major protected or unable to give consent ;
* Pregnant women ;
* Vulnerable persons defined by French legislation.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
In vitro spontaneous CD62P (P-selectin) expression level
Timeframe: 90 Days
2
In vitro spontaneous CD63 (membrane protein) expression level
Timeframe: 90 Days
3
In vitro CD62P (P-selectin) expression level after a CMV antigen stimulation
Timeframe: 90 Days
4
In vitro CD63 (membrane protein) expression level after a CMV antigen stimulation